| Placebo (n = 32) | Real (n = 30) |
---|---|---|
Sex | Â | Â |
 Male | 30 | 27 |
 Female | 2 | 3 |
Age, mean (SD), years | 71.9 (7.0) | 72.1 (7.0) |
Body mass index, mean (SD), kg/m2 | 21.3 (3.9) | 21.7 (3.9) |
Modified MRC dyspnea scale, mean (SD) | 1.9 (1.2) | 2.2 (1.0) |
Brinkman index, mean (SD)a | 1461.0 (775.7) | 1258.2 (512.4) |
GOLD criteria | Â | Â |
 II | 13 | 6 |
 III | 7 | 13 |
 IV | 12 | 11 |
Home oxygen therapy | 10 | 8 |
6MWT | Â | Â |
 6MWD, mean (SD), m | 405.2 (111.2) | 373.2 (115.2) |
 Leg fatigue, Borg scale, mean (SD) | 5.1 (1.9) | 5.7 (3.3) |
 Dyspnea, Borg scale, mean (SD) | 4.2 (2.7) | 5.5 (2.8) |
 SpO2, mean (SD), % lowest value | 88.3 (6.1) | 86.0 (7.0) |
Pulmonary function, mean (SD) | Â | Â |
 VC, L | 3.15 (0.67) | 2.88 (0.52) |
 VC, % predicted | 100.3 (19.4) | 94.6 (14.1) |
 IC, L | 1.91 (0.50) | 1.75 (0.37) |
 ERV, L | 1.25 (0.32) | 1.13 (0.38) |
 FVC, L | 2.99 (0.67) | 2.79 (0.55) |
 FEV1, L | 1.15 (0.41) | 1.04 (0.30) |
 FEV1, % predicted | 47.9 (16.7) | 46.0 (16.6) |
 FEV1/FVC, % | 38.1 (11.3) | 37.8 (11.8) |